超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

Marinomed?
Marinomed Biotechnologie GmbH 創立于2006年，在一個創新的抗病毒呼吸技術平臺基礎上開發呼吸系統疾病的治療藥物。該技術的首個上市產品是一種抗病毒鼻腔噴霧劑，已證明該技術安全有效，具有實用性。Marinomed 在流感、抗哮喘藥合劑和其他高危患者方面也有進一步的專攻產品，體現出該技術的巨大潛力。此外，該公司還開發一種針對I型變態反應和自身免疫疾病的新藥。Marinomed Biotechnologie GmbH是從維也納獸醫大學分拆出來的公司，總部在奧地利維也納。

?

Marinomed is a biopharmaceutical company discovering and developing innovative anti-viral and immunological treatments.

Marinomed has devoted its discovery and research efforts to the evolution of MAVIREX, a technology platform for the development of therapies that target more than 200 different respiratory virus strains based on polymers derived from red seaweed. The huge potential of this technology is reflected by Carragelose?, a unique broadly active anti-viral compound for treating respiratory diseases. Safety and antiviral effectiveness have been established in clinical trials involving both adults and children. The compound is approved for marketing in the EU as part of an anti-viral nasal spray targeting common cold.

Further novel anti-viral products derived from MAVIREX are currently being developed. These products comprise combinations with known compounds in the respiratory field, including influenza. Marinomed also develops products for at-risk patients for the prevention and treatment of respiratory virus infections that may cause a worsening of an underlying disease such as asthma, allergic rhinitis and COPD.

In addition, the Company develops novel treatments against Type I allergy and autoimmune diseases.

Marinomed is located in Vienna, Austria and was founded in March 2006 as a spin-off from the Veterinary University of Vienna.